HC Wainwright & Co. : The ASLAN Pharma (ASLN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
ASLAN Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF) and Aslan Pharmaceuticals (ASLN)
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Astria Therapeutics (ATXS) and Aslan Pharmaceuticals (ASLN)
HC Wainwright & Co. : The ASLAN Pharma (ASLN.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
ASLAN Pharma Analyst Ratings
ASLAN Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Rewalk Robotics (LFWD) and Apellis Pharmaceuticals (APLS)
ASLAN Pharma Analyst Ratings
HC Wainwright & Co. Maintains Buy on ASLAN Pharma, Lowers Price Target to $9
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Urogen Pharma (URGN) and Legend Biotech (LEGN)
ASLAN Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Legend Biotech (LEGN) and Aslan Pharmaceuticals (ASLN)
ASLAN Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $17 Price Target
ASLAN Pharma Analyst Ratings
Promising Drug Development Progress Boosts Aslan Pharmaceuticals' Buy Rating: An Analysis of Eblasakimab's Potential in Treating AD and COPD
Piper Sandler Reaffirms Their Buy Rating on Aslan Pharmaceuticals (ASLN)
Aslan Pharmaceuticals: Promising Financial Results and Optimistic Drug Trial Outcomes Boost Buy Rating
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Prime Medicine, Inc. (PRME) and HealthStream (HSTM)
No Data